In this clinical trial, we are studying a new drug under development for the treatment of malaria. This disease is caused by a parasite that is transmitted through infected mosquitoes.
The medicine is not yet approved for sale and will be given orally (by mouth). The study consists of 3 panels (A, B and C). We are currently looking for candidates for Panels A and B, each with 8 subjects per panel. You can only participate in 1 panel.
The study consists of 2 preliminary studies, 4 treatment periods and a final study. Preliminary investigations will take place on 29 or 30 September (Box A) and on 6 or 10 October (Box B)
–
